LAS VEGAS — Ashkan M. Abbey, MD, presented 1-year fellow eye substudy results for ABBV-RGX-314, a subretinal gene therapy from Regenxbio for wet age-related macular degeneration.
At Clinical Trials at the Summit, Abbey addressed concerns about using gene therapy in both eyes. However, in 11 eyes that were treated bilaterally, there were no significant serious adverse events or major inflammation. Additionally, the bilateral treatment showed efficacy, with a reduced treatment burden.
“Sixty percent of [patients] were supplemental injection-free after 1 year of receiving the